Connect with us

Medical Marijuana

Marijuana Retail Report

Published

3 months ago

on

Marijuana Retail Report



“West Virginia Needs to Plan Better for the Future”

Despite a veto that could have delayed it even more spent $38 million on medical marijuana collected over the past four years, state Treasurer Larry Pack (R) now says he will release the funds as originally mandated.

Last week, Gov. Patrick Morrissey (R) vetoed a bill that would have required funding for medical marijuana to help the homeless and expedite child abuse and neglect cases in the court system. He said the bill would tie up money for future spending.

In his veto letter, Morrissey wrote, “West Virginia needs to do a better job of planning for the future, and it cannot preemptively lock in such future revenue streams when it has the reserves to invest more in roads, water, sewer, site selection, rail and future tax cuts.”

Morrissey said he is willing to negotiate with the Legislature on how to spend the money.

To read the rest of this article on marijuana moment, Click here

Related Topics:
Continue Reading

Glass House

Marijuana Retail Report

Published

3 days ago

on

June 21, 2026

By

Marijuana Retail Report



The company previously announced plans to separate adult and medical use

After set script, another public cannabis operator separated its medical marijuana from adult marijuana in an attempt to go public on the New York Stock Exchange.

But California-based vertically integrated operator Glass House Brands said in documents filed Thursday that it plans to go further than listing on the NYSE. In particular, the company stated that it is preparing for export and interstate trade.

The company previously said in a press release on Wednesday that it had applied to list on the NYSE after “unbundling” its medical and adult businesses.

If successful, Glass House would become the second U.S. cannabis company to go public on a major U.S. exchange, following Florida-based multi-state marijuana operator Trulieve Cannabis Corp.

To read the rest of this article on MJ Biz Daily, Click here

Continue Reading

Federal

Anti-Rescheduling Parties Ask Court To Stay Schedule III Cannabis Order

Published

2 weeks ago

on

June 12, 2026

By

Anti-Rescheduling Parties Ask Court To Stay Schedule III Cannabis Order

A national organization that promotes drug-free workplaces and a pharmaceutical company that specializes in cannabinoids filed a petition in federal court on June 9 to try to stop the Trump administration’s immediate devolution of medical cannabis.

The National Drug and Alcohol Administration Association (NDASA) and MMJ International Holdings, whose subsidiary has an active DEA Schedule I analytical laboratory registration, asked the U.S. Court of Appeals for the District of Columbia Circuit on April 22 to stop U.S. Attorney General Todd Blanche from acting. signed an order reclassifying the state license for medical cannabis to Schedule III until the court case to set aside the entire order is decided.

The plaintiffs argue that the court must consider four factors:

  1. A lawsuit between the human rights group NORML and the Drug Enforcement Administration (DEA) nearly 50 years ago;
  2. The transfer order “illegally” bypassed regulatory notice and comment;
  3. Two plaintiffs will “suffer irreparable harm” without a stay; and
  4. The balance of equity and public interest.

To read the rest of this article on Cannabis Business Times, Click here

Post Parties opposing deadline ask court to delay Schedule III cannabis order first appeared on Marijuana Retail Report – News and information for cannabis retailers.

Continue Reading

alabama

Marijuana Retail Report

Published

2 weeks ago

on

June 8, 2026

By

Marijuana Retail Report



Sales under the state license began today

Patients who meet state requirements can finally access approved medical cannabis products from licensed dispensaries in Alabama.

Selling with a state license began today, more than five years after lawmakers adopted legislation regulation of the medical marijuana market. For years, the program’s rollout has been delayed by litigation — at one time with regulators suspension licensing process in general.

“For five long years, Alabama patients have not been able to locally obtain medically necessary, state-approved cannabis products from state-licensed dispensaries,” said NORML Deputy Director Paul Armentano. “These unwarranted delays have caused unnecessary suffering and needlessly put the health and well-being of patients at risk. Starting today, lawmakers, regulators and licensed providers must start putting patients’ needs first.”

To read the rest of this article on NORML, Click here

Continue Reading
Advertisement

Trending

Copyright © 2021 The Art of MaryJane Media